Two sisters from Lara have been diagnosed with the same rare form of leukaemia within 16 months, forcing their family into ...
Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) ...
Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss ...
Sources close to a closed-door State House meeting on Tuesday talked of a unanimous vote backed by President Museveni ...
Despite the late-stage miss, analysts maintained confidence in the Epkinly program, with Truist Securities saying the result ...
The FDA's orphan drug designation supports LP-284's development for soft tissue sarcomas, addressing significant unmet needs in this adult patient population. The FDA granted orphan drug designation ...
Ascentage Pharma receives US FDA’s IND clearance for BTK degrader APG-3288 to treat patients with relapsed/refractory B-cell malignancies: Rockville, Maryland Friday, January 9, ...
Preliminary total global full year 2025 revenue of approximately $616 millionPreliminary BRIUMVI U.S. fourth quarter and full year 2025 net ...
A recent study by Vanderbilt Health researchers has revealed a greater, detrimental role for B lymphocytes (B cells) in the ...
Janux Therapeutics Inc., a clinical-stage biopharmaceutical company, has appointed William Go, M.D., Ph.D., as its Chief ...
Novartis intends to submit ianalumab for regulatory approval globally in early 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results